JPRN-UMIN000020688已完成2 期
Phase 2 study of low-dose Afatinib maintenance therapy for patients with EGFR-mutated non-small-cell lung cancer - Phase 2 study of low-dose Afatinib maintenance therapy for patients with EGFR-mutated non-small-cell lung cancer
orth Japan Lung Cancer Study Group0 个研究点目标入组 30 人开始时间: 2016年1月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. previously treated by EGFR-TKI 2. admitted EGFR gene mutation of T790M or exon20 insertion 3. symptomatic brain metastasis 4. with interstitial pneumonia or pulmonary fibrosis 5. with active other malignancies 6. with massive effusion required tube drainage 7. with active infection 8. with severe comorbidities 9. with other conditions that is considered inappropriate for the study by an attending physician
研究者
相似试验
已完成
2 期
A phase 2 study of first line low dose afatinib in advanced non-small-cell lung cancer patients with mutated epidermal growth factor receptoron-small cell lung cancerJPRN-UMIN000016444Kyoto Thoracic Oncology Research Group (KTORG)45
已完成
2 期
Phase II Study of First-Line Afatinib in Patients Aged 75 or Older With Advanced Lung Adenocarcinoma With EGFR MutationsElderly patients with NSCLC harboring sensitive EGFR mutationJPRN-UMIN000015834Osaka Lung Cancer Study Group38
进行中（未招募）
2 期
A phase 2 study of afatinib for NSCLC with uncommon EGFR mutation detected by NGSon-small cell lung cancer with uncommon EGFR mutaitonJPRN-jRCTs041190027Takahashi Toshiaki17
进行中（未招募）
1 期
Afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancerPatients with histological or cytological proof of advanced KRAS mutant and PIK3CA wildtype non small cell lung cancer (NSCLC) and colorectal cancer (CRC). In part B: for which first-line treatment failed.MedDRA version: 21.1 Level: PT Classification code 10029520 Term: Non-small cell lung cancer stage IIIA System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029518 Term: Non-small cell lung cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001855-22-NLetherlands Cancer Institute- Antoni van Leeuwenhoek Hospital140
进行中（未招募）
2 期
EJ025Bon-sequamous non-small cell lung cancerJPRN-jRCTs021200005Maemondo Makoto35